Drugs / 4SCAR-276
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04432649 | Jun 2026 → Dec 2029 expected | neoplasm | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SCAR-276 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04432649 ↗ |
| Target | CD276 | “targeting CD276” NCT04432649 ↗ |